Comprehensive Analysis Of Ranitidine Usage: Pharmacological Interactions, Safety In Polypharmacy And Effects On Disease Management
Keywords:
Ranitidine, Adverse drug reaction, GERD, PolypharmacyAbstract
Background: The selective histamine type 2 receptor antagonists/blockers (H2 blockers) are widely used in the treatment of acid-peptic disease, including duodenal and gastric ulcers, gastroesophageal reflux disease, and common heartburn.
Aim And Objectives: To comprehensively evaluate the indications, pharmacological interactions, and safety profile of ranitidine in polypharmacy prescriptions within the general medicine department.
Methodology:The six-month observational cross-sectional study was conducted in a tertiary care teaching hospital. Informed consent was collected from all the participants. All the patients (363) were monitored for drug interactions and adverse drug reactions.
Results And Discussion: Results showed that in this study, 54.2% of participants used ranitidine for non-labeled indications, exceeding the 45.7% who used it for approved purposes. Out of 363 study participants, 45.7% (166) were prescribed ranitidine for labeled indications (such as GI ulcers and GERD), aligning with approved uses for acid suppression. Rashes are the most frequent ADR, affecting 50.6% of patients, indicating a notable dermatological impact. Bradyarrhythmia, observed in 38.51% of cases, underscores the need for vigilant cardiac monitoring due to its serious nature. Out of 363, 204(56.19%) prescriptions are inappropriate polypharmacy, and among these, deprescribing is done in 56 prescriptions, and dose adjustment made in 20 prescriptions.
Conclusion: The comprehensive analysis of ranitidine usage reveals a high prevalence of conditions that may be affected by ranitidine therapy due to inappropriate use. This study highlights the importance of closely monitoring pharmacological interactions in polypharmacy, especially when using ranitidine among patients with complex health profiles.
Downloads
Metrics
References
Histamine Type-2 Receptor Antagonists (H2 Blockers) [Updated 2018 Jan 25].
Brogden RN, Carmine AA, Heel RC et al. Ranitidine: A Review of its Pharmacology and Therapeutic Use in Peptic Ulcer Disease and Other Allied Diseases. Drugs.1982: 24;267– 303.
White CM. Ranitidine's N-nitrosodimethylamine problem may be tip of the iceberg. JAMA Netw Open .2021;4:e2035158.
MacFarlane B. Management of gastroesophageal reflux disease in adults: a pharmacist's perspective. Integr Pharm Res Pract. 2018;7:41-52.
A glossary of terms for community health care and services for older persons. Geneva: World Health Organization; 2004 (http://apps.who.int/iris/bitstream/handle/10665/6 8896/WHO_WKC_Tech.Ser._04.2.pdf?sequence=1 &isAllowed=y, accessed 20 March 2019).
High-Alert Medications In Community/Ambulatory Settings. In: Institute for Safe Medication Practices [website]. Horsham (PA): Institute for Safe Medication Practices; 2011 (https://www.ismp.org/recommendations/high alert-medications-communityambulatory-list, accessed 20 March 2019).
Russom M, Desta Z, Gebrehiwot H, et al. Ranitidine-Induced Cardiac Arrest: A Case Series and Review of the Literature. Drug Saf Case Rep. 2021;8(1):1-7. doi:10.1007/s40800-02100255-3.
Brodie MJ & Macphee GJA: Carbamazepine neurotoxicity precipitated by diltiazem. Br Med J 1986; 292:1170-1171.
Summers MA, Moore JL.McAuley JW. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Ann Pharmacother. 2004; 38:1631-1634.
Thomson W, Farrell B. Deprescribing. what is it and what does the evidence tell us? Can J Hosp Pharm. 2013;66(3):201-2.
George J, Majeed IA, Joseph S, et al. Rational Use of Ranitidine in a General Hospital: Impact of an Educational Intervention. J Clin Pharm Ther. 2001;26(5):1-5.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
